Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study

Metastatic Pancreatic Cancer: Emerging Strategies in Chemotherapy and Palliative Care

“…Almost 24% of patients treated with gemcitabine experienced a clinical benefit with regard to improved pain and/or fatigue [21][22][23].…”

“…El Kamar, Grossbard, Kozuch 21 versus placebo, prior to stenting. There was a 1.2% increase in body weight in the group of patients assigned to receive the pancreatic enzymes versus 3.7% decrease in body weight for the placebo group [55].…”

Treatment of Non-Resectable Pancreatic Cancer With 5-Fluorouracil, Leucovorin and Mitomycin-C

“…The complete response has continued for 36 months after the initial surgery. , 1996), leucovorin (Oman, Blind, Naredi et al, 2001;Huguier, Barrier, Valinas et al, 2001;Oettle, Arning, Pelzer et al, 2000;Andre, Balosso, Louvet et al, 2000;Kornek, Schratter-Sehn, Marczell et al, 2000;Link, Formentini, Papachristov et al, 1997;Raderer, Kornek, Hejna et al, 1997) and interferons were used with 5-FU as biochemical modulators, and epirubicin (Raderer , Kornek, Hejna et al, 1997), mitomycin, cyclophosphamide and many other agents were used in an attempt to gain synergistic effects . Weekly 5-FU with leucovorin, daily dipyridamole and intermittent mitomycin-C was reported to be effective palliative, neoadjuvant and adjuvant chemotherapy for pancreatic cancer Todd, Gloor, Lane et al, 1998).…”

“…Systemic chemotherapy is an alternative treatment for patients with advanced and unresectable pancreatic cancer and many clinical trials have been performed in an attempt to find the optimal anti-cancer drug regimen. The combination of 5-FU and leucovorin has been shown to have some anti-cancer effect in patients with advanced gastrointestinal and pancreatic cancer (Oman, Blind, Naredi et al, 2001;Huguier, Barrier, Valinas et al, 2001;Oettle, Arning, Pelzer et al, 2000;Andre, Balosso, Louvet et al, 2000;Kornek, Schratter-Sehn, Marczell et al, 2000). However, the results for pancreatic cancer were far from satisfactory with a maximal response rate of 20-30% with either mono-or combination therapy.…”

Adjuvant therapy for pancreatic cancer

“…Ishikawa et al [70] 1994 23 EBRT 17/23 7 4 22 Coia et al [71] 1994 27 EBRT + 5-FU + MMC 13/27 4 8 0/13 1 6 43 Staleyet al [72] 1996 39 EBRT + 5-FU + IORT 39/39 100 7/39 1 9 19 (4 year) Spitz et al [73] 1997 [74] 1998 53 EBRT + 5-FU + MMC 24/53 4 5 15.7 White et al [75] 1999 25 5-FU + EBRT + MMC +CPP 5/25 2 0 Wanebo et al [76] 2000 14 5-FU + EBRT +CPP 9/14 6 4 Snady et al [77] 2000 68 EBRT+5-FU+STREP+CPP 20/68 2 9 3 2 32 48 NR 7 1 2 1 13 EBRT = external beam radiotherapy; 5-FU = 5-fluorouracil; MMC= mitomycin C; IORT = intraoperative radiotherapy; STP = streptozocin; CDDP = cisplatinum; FA = folinic acid; DPD = dipyridamole; n = number; CPP=cisplatin; NR = not resectable. [86] 1999 23 EBRT 5-FU + FA 15.9 Paulino et al [87] 1999 30 EBRT 5-FU 26 8 EBRT 5.5 André et al [88] 2000 …”